Objective: The pathogenesis of postherpetic neuralgia is not clear, the pain is severe, the duration is long, and the treatment effect is poor. We explored the potential mechanism of sinomenine in the treatment of postherpetic neuralgia based on single-cell sequencing and molecular docking technology and provided a theoretical basis for studying the pathogenesis of postherpetic neuralgia.
Methods: Based on single-cell sequencing analysis and bioinformatics, the possible pain-causing factors of postherpetic neuralgia were identified, and the interaction between sinomenine and the target protein was analyzed using the molecular docking technique. First, the genes related to sinomenine and postherpetic neuralgia were found through various databases. Then, single-cell gene sequencing was used to identify pain-related marker genes and their role in cell subsets. The intersection of the differentially expressed (|LogFC|>1) marker gene and the postherpetic neuralgia-related genes in single-cell sequencing was used as the postherpetic neuralgia pain-causing gene set. Intersection of sinomenine and hub genes was used to identify the target genes that interact with each other, and sinomenine was molecularly docked with the target genes.
Results: A total of 2524 postherpetic neuralgia-related genes and 43 sinomenine-related genes were identified through Genecard, CTD, and the GEO database. Single-cell gene sequencing was performed and revealed a total of 680 marker genes between pain and pain-free cell populations |logFC|>1. Pain-associated subpopulations were annotated mainly with microglia and astrocytes. And there were 125 intersection genes associated with postherpetic neuralgia. These genes were associated with the development of postherpetic neuralgia. 42 hub gene were identified from these crossover genes. MMP2 is the common gene of hub genes and sinomenine-related genes. Molecular docking discovers better affinity and stability between sinomenine and MMP2 protein.
Conclusion: This study combined single cell analysis, bioinformatics and molecular docking to identify MMP2 as a potential target for sinomenine in the treatment of postherpetic neuralgia, which may act on microglia to alleviate pain by regulating the neuroinflammatory response and ion pathways.